Puma biotechnology, inc. (PBYI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Sep'11
Revenue:
Total revenue

272,260

250,991

27,685

-

-

-

-

-

-

0

Operating costs and expenses:
Cost of sales

36,815

34,621

5,572

-

-

-

-

-

-

-

Selling, general and administrative

141,692

146,188

106,693

53,798

31,808

19,358

9,787

24,814

9,331

-

Research and development

132,851

164,854

207,810

222,798

208,472

122,917

45,046

49,636

826

-

Total operating costs and expenses

311,358

345,663

320,075

276,596

240,280

142,275

54,833

74,450

10,157

379

(Loss) profit from operations

-39,098

-94,672

-292,390

-276,596

-240,280

-142,275

-54,833

-74,450

-10,157

-379

Other income (expenses):
Interest income

2,847

1,796

1,256

958

971

324

172

98

4

-

Interest expense

15,019

10,985

720

-

-

-

-

-

-

-

Legal verdict expense

16,350

9,000

-

-

-

-

-

-

-

-

Loss on debt extinguishment

-8,103

-

-

-

-

-

-

-

-

-

Other income (expenses)

128

-714

-101

-373

25

-14

2

-

-80

-

Total other expenses

-36,497

-18,903

435

585

996

310

174

98

-76

-13

Net loss

-75,600

-113,575

-291,955

-276,011

-239,284

-141,965

-54,659

-74,352

-10,233

-392

Net loss applicable to common stockholders

-75,595

-113,575

-291,955

-276,011

-239,284

-141,965

-54,659

-74,352

-10,233

-392

Net loss per share of common stock—basic and diluted

-1.95

-2.99

-7.85

-8.29

-7.45

-4.73

-1.90

-3.42

-1.32

-

Weighted-average shares of common stock outstanding—basic and diluted

38,768

37,942

37,169

33,295

32,126

30,010

28,696

21,725

7,746

-

Product Revenue, Net
Total revenue

211,619

200,491

26,185

-

-

-

-

-

-

-

License Revenue
Total revenue

60,250

50,500

1,500

-

-

-

-

-

-

-

Royalty Revenue
Total revenue

391

-

-

-

-

-

-

-

-

-